- Home
- EDD vs TNGX Comparison
EDD vs TNGX Comparison
Compare EDD & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- TNGX
- Stock Information
- Founded
- EDD 2007
- TNGX 2014
- Country
- EDD United States
- TNGX United States
- Employees
- EDD N/A
- TNGX N/A
- Industry
- EDD Finance Companies
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EDD Finance
- TNGX Health Care
- Exchange
- EDD Nasdaq
- TNGX Nasdaq
- Market Cap
- EDD 331.9M
- TNGX 351.2M
- IPO Year
- EDD N/A
- TNGX N/A
- Fundamental
- Price
- EDD $5.14
- TNGX $6.01
- Analyst Decision
- EDD
- TNGX Strong Buy
- Analyst Count
- EDD 0
- TNGX 6
- Target Price
- EDD N/A
- TNGX $12.20
- AVG Volume (30 Days)
- EDD 254.3K
- TNGX 2.7M
- Earning Date
- EDD 01-01-0001
- TNGX 08-06-2025
- Dividend Yield
- EDD 7.52%
- TNGX N/A
- EPS Growth
- EDD N/A
- TNGX N/A
- EPS
- EDD N/A
- TNGX N/A
- Revenue
- EDD N/A
- TNGX $40,990,000.00
- Revenue This Year
- EDD N/A
- TNGX N/A
- Revenue Next Year
- EDD N/A
- TNGX N/A
- P/E Ratio
- EDD N/A
- TNGX N/A
- Revenue Growth
- EDD N/A
- TNGX 10.09
- 52 Week Low
- EDD $4.22
- TNGX $1.03
- 52 Week High
- EDD $4.95
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- EDD 56.59
- TNGX 76.36
- Support Level
- EDD $5.12
- TNGX $5.34
- Resistance Level
- EDD $5.26
- TNGX $6.40
- Average True Range (ATR)
- EDD 0.07
- TNGX 0.50
- MACD
- EDD -0.01
- TNGX -0.02
- Stochastic Oscillator
- EDD 36.00
- TNGX 84.08
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.